Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.7150/ijbs.47652 http://scihub22266oqcxt.onion/10.7150/ijbs.47652 32760206!7378642!32760206     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Biol+Sci 2020 ; 16 (13): 2382-2391 Nephropedia Template TP {{tp|p=32760206|t=2020. Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels |pdf=|usr=}}{{32760206}} gab.com Text Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels JO: Int J Biol Sci http://www.kidney.de/pget.php?&tw=1&pmid=32760206 #FOAvip COVID-19 is a public health emergency that has rapidly spread to over 200 countries and regions, and no effective treatment has been established to date. Severe and critical cases have been associated with higher mortality due to acute respiratory distress syndrome (ARDS) and cytokine storm. Based on the novelty and recent emergence of COVID-19, no effective treatment regimen has been identified, thus prompting clinicians to engage in drug repurposing to address the immediate therapeutic need. This study focused on the molecular target angiotensin-converting enzyme 2 (ACE2) of SARS-CoV-2 and screened a group of ACE2 agonists by bioinformatics. Glucocorticoids are a type of ACE2 activator. We verified the efficacy of nine chemicals on regulating ACE2 expression in human GES-1, an upper digestive tract epithelial cell line, and THP-1, a human monocyte cell line, and found that several glucocorticoids imparted activating effects on ACE2 in both cell lines. The drugs triciribine and kinetin riboside activate ACE2 expression or inhibit IL-6 production in macrophages to some extent. In addition, we compared the efficacies of several glucocorticoids. Hydrocortisone showed the strongest effect on ACE2 activation, followed by prednisolone, dexamethasone, and methylprednisolone. We retrospectively analyzed the therapeutic efficacy of nine severe or critical patients from a cohort of 90 COVID-19 cases, who received medium to small doses of glucocorticoids from our integrated medical team in Wuhan. Seven out of nine patients revealed significant improvement in clinical parameters and chest CT images. This study provides experimental and clinical evidence that medium-to-low-dose glucocorticoids may play a protective role in the respiratory and digestive systems by activating ACE2 and suppressing cytokine storm. Twit Text FOAVip Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels ????Int J Biol Sci http://www.kidney.de/pget.php?&tw=1&pmid=32760206 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32760206 #FOAvip English Wikipedia <ref>{{Cite pmid|32760206}}</ref> Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels #MMPMID32760206 Xiang Z; Liu J; Shi D; Chen W; Li J; Yan R; Bi Y; Hu W; Zhu Z; Yu Y; Yang Z Int J Biol Sci 2020[]; 16 (13): 2382-2391 PMID32760206show ga COVID-19 is a public health emergency that has rapidly spread to over 200 countries and regions, and no effective treatment has been established to date. Severe and critical cases have been associated with higher mortality due to acute respiratory distress syndrome (ARDS) and cytokine storm. Based on the novelty and recent emergence of COVID-19, no effective treatment regimen has been identified, thus prompting clinicians to engage in drug repurposing to address the immediate therapeutic need. This study focused on the molecular target angiotensin-converting enzyme 2 (ACE2) of SARS-CoV-2 and screened a group of ACE2 agonists by bioinformatics. Glucocorticoids are a type of ACE2 activator. We verified the efficacy of nine chemicals on regulating ACE2 expression in human GES-1, an upper digestive tract epithelial cell line, and THP-1, a human monocyte cell line, and found that several glucocorticoids imparted activating effects on ACE2 in both cell lines. The drugs triciribine and kinetin riboside activate ACE2 expression or inhibit IL-6 production in macrophages to some extent. In addition, we compared the efficacies of several glucocorticoids. Hydrocortisone showed the strongest effect on ACE2 activation, followed by prednisolone, dexamethasone, and methylprednisolone. We retrospectively analyzed the therapeutic efficacy of nine severe or critical patients from a cohort of 90 COVID-19 cases, who received medium to small doses of glucocorticoids from our integrated medical team in Wuhan. Seven out of nine patients revealed significant improvement in clinical parameters and chest CT images. This study provides experimental and clinical evidence that medium-to-low-dose glucocorticoids may play a protective role in the respiratory and digestive systems by activating ACE2 and suppressing cytokine storm. |Adenosine/therapeutic use[MESH] |Adult[MESH] |Aged[MESH] |Angiotensin-Converting Enzyme 2[MESH] |Antiviral Agents/therapeutic use[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Cell Line[MESH] |Cell Line, Tumor[MESH] |Coronavirus Infections/*drug therapy/metabolism[MESH] |Cytokines/metabolism[MESH] |Epithelial Cells/virology[MESH] |Female[MESH] |Gene Expression Regulation, Neoplastic[MESH] |Glucocorticoids/*therapeutic use[MESH] |Humans[MESH] |Hydrocortisone/therapeutic use[MESH] |Interleukin-6/*metabolism[MESH] |Kinetin/therapeutic use[MESH] |Macrophages/drug effects[MESH] |Male[MESH] |Middle Aged[MESH] |Monocytes/virology[MESH] |Pandemics[MESH] |Peptidyl-Dipeptidase A/*metabolism[MESH] |Pneumonia, Viral/*drug therapy/metabolism[MESH] |Retrospective Studies[MESH] |Ribonucleosides/therapeutic use[MESH] |SARS-CoV-2[MESH]Glucocorticoids improve severe or critical COVID-19 by activating ACE2(epmc).pdf DeepDyve Pubget Overpricing